Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Bioanalysis ; 2(8): 1405-14, 2010 Aug.
Article in English | MEDLINE | ID: mdl-21083341

ABSTRACT

BACKGROUND: A defined approach to develop and validate an LC-MS/MS assay using dried blood spot (DBS) samples is of great interest to many scientists who are adopting this technology. We have evaluated three distinct sample preparation procedures of DBS samples for LC-MS/MS assay development. RESULTS: A new term 'elution efficiency' is introduced to evaluate the effectiveness of eluting compounds from the DBS cards into the liquid phase. Three different types of DBS cards were studied as part of the sample preparation procedures. A DBS LC-MS/MS method was developed, qualified and then applied to a toxicokinetics study. CONCLUSION: Organic extraction and protein precipitation resulted in significant ion suppression and/or enhancement for FTA(®) Classic or FTA(®) Elute cards. Liquid-liquid extraction produced the least ion suppression/enhancement. Both protein precipitation and liquid-liquid extraction effectively eluted the probe compound from the DBS cards under the conditions tested. However, organic extraction by pure solvents resulted in low elution efficiency.


Subject(s)
Analytic Sample Preparation Methods/methods , Blood Chemical Analysis/methods , Blood Specimen Collection/methods , Chromatography, High Pressure Liquid/methods , Tandem Mass Spectrometry/methods , Animals , Blood Proteins/chemistry , Chemical Precipitation , Desiccation , Pharmacokinetics , Rats , Terminology as Topic
2.
Anal Chem ; 82(9): 3834-9, 2010 May 01.
Article in English | MEDLINE | ID: mdl-20387806

ABSTRACT

Metabolomics with chromatography-mass spectrometry is often challenging and relies on statistical tools to discern changes in a metabolome. A pooled sample strategy was proposed, consisting of (1) identification of potential marker candidates by detecting changes of metabolites in a few pooled samples between treated and control groups and (2) validation of markers of statistically significant changes with a large set of individual samples. This strategy was enabled by applying a thorough background subtraction approach based on high-resolution mass spectrometry. In a proof-of-principle study, plasma samples were generated and pooled in a 6-week investigational study to identify potential toxicological markers for an observed muscle toxicity associated with the treatment of ibipinabant in dogs. With pooled control samples as backgrounds, potential marker candidates were revealed in the background-subtracted profiles of the pooled ibipinabant-treated samples. After further cleaning with the use of mass defect filtering to exclude drug metabolites and the comparison of profiles between pooled treated samples to eliminate inconsistent peaks, the major biomarker candidates in the profiles were identified to be 19 acylcarnitines. A total of 3 of the 19 acylcarnitines were measured on the set of individual samples to allow for statistical analysis. The results confirmed the significance of acylcarnitine elevations in ibipinabant-treated dogs and indicated that the acylcarnitines could be early markers for the dog-specific toxicity. The advantages of the pooled sample strategy and its potential limitations for metabolomics are discussed.


Subject(s)
Biomarkers/analysis , Cannabinoid Receptor Modulators/therapeutic use , Chromatography, High Pressure Liquid , Mass Spectrometry , Pyrazoles/toxicity , Pyrazoles/therapeutic use , Sulfonamides/toxicity , Sulfonamides/therapeutic use , Animals , Cannabinoid Receptor Modulators/adverse effects , Cannabinoid Receptor Modulators/toxicity , Chromatography, High Pressure Liquid/methods , Dog Diseases/drug therapy , Dogs , Humans , Obesity/drug therapy , Obesity/veterinary
3.
Pharmacogenet Genomics ; 18(10): 903-10, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18794727

ABSTRACT

OBJECTIVE: Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists can cause peripheral edema in susceptible individuals. To investigate the mechanistic basis underlying this adverse event, we performed a candidate gene analysis of patients enrolled in clinical trials of muraglitazar, an investigational PPARalpha/gamma dual agonist, and developed a cell culture-based gene expression assay and nonhuman primate model of edema to study the edemagenic properties of PPARgamma agonists. METHODS: A total of 213 single nucleotide polymorphisms (SNPs) in 63 genes were genotyped in 730 participants. Chi-square and logistic regression analyses were used to test for association with edema. Transcriptional responses to PPARgamma agonists were evaluated in Calu-6 cells using quantitative real-time PCR. Male Cynomolgus monkeys were treated with PPAR agonists and were evaluated for edema using MRI. RESULTS: SNPs in renin (rs2368564) and endothelin-1 (rs5370) were associated with reduced risk of edema (P=0.003 and P=0.028, respectively) and an SNP in beta1 adrenergic receptor (rs1801253) was associated with increased susceptibility to edema (P=0.034). Gene expression studies revealed that renin and endothelin-1 were regulated by PPARgamma in Calu-6 cells. A survey of 10 PPARgamma agonists further revealed that a compound's in vitro potency was correlated with its edemagenic potential leading to the prediction that one of three previously uncharacterized PPARgamma agonists would cause less edema. This prediction was validated in a nonhuman primate model of PPARgamma agonist-induced edema. CONCLUSION: Our results implicate a key role for renin and endothelin-1 in the edema caused by PPARgamma agonists and demonstrate how knowledge gained from pharmacogenetic studies can be applied in drug discovery.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/genetics , Edema/metabolism , Endothelin-1/biosynthesis , Gene Expression Regulation , PPAR gamma/agonists , PPAR gamma/metabolism , Pharmacogenetics/methods , Polymorphism, Single Nucleotide , Renin/biosynthesis , Animals , Female , Glycine/analogs & derivatives , Glycine/pharmacology , Humans , Macaca fascicularis , Male , Oxazoles/pharmacology , Regression Analysis
4.
Breast Cancer Res Treat ; 103(3): 331-41, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17061046

ABSTRACT

Increased breast cancer risks have been reported among women with gross cystic breast disease (GCBD), although the mechanism for this increase remains unexplained. Relationships between GCBD characteristics, breast cancer risk factors, and the biochemical composition and growth properties of 142 breast cyst fluid (BCF) samples were studied among 93 women with GCBD. Concentrations of melatonin, estrogen (17-beta-estradiol), dehydroepiandrosterone-sulfate (DHEA-S), epidermal growth factor (EGF), transforming growth factor beta (TGF-B1 and TGF-B2), sodium (Na), and potassium (K) were quantified in BCF samples, and human breast cancer cells (MCF-7) were treated with BCF in vitro. Patients were grouped according to BCF Na:K ratios previously linked with increased breast cancer risks (Na:K 3, Type 2) and mixed cyst groups. Women with larger and more frequently occurring cysts had higher BCF estrogen and DHEA-S, and lower TGF-B1 levels. Women with Type 1 cysts had elevated BCF melatonin, estrogen, DHEA-S, and EGF, and lower concentrations of TGF-B2 compared to women with Type 2 cysts. BCF generally inhibited cell growth relative to serum-treated controls, consistent with previous studies. Melatonin and estrogen in BCF independently predicted growth inhibition and stimulation, respectively. Biological monitoring of BCF may help identify women with GCBD at greatest risk for breast cancer development.


Subject(s)
Breast Cyst/metabolism , Breast Neoplasms/metabolism , Cyst Fluid/metabolism , Estrogens/biosynthesis , Gene Expression Regulation, Neoplastic , Melatonin/biosynthesis , Adult , Cell Line, Tumor , Dehydroepiandrosterone Sulfate/chemistry , Epidermal Growth Factor/biosynthesis , Estradiol/biosynthesis , Female , Humans , Middle Aged , Transforming Growth Factor beta/biosynthesis
5.
Toxicol Lett ; 146(3): 197-205, 2004 Feb 02.
Article in English | MEDLINE | ID: mdl-14687757

ABSTRACT

An evaluation of high-throughput Fourier-transform infrared spectroscopy (FT-IR) as a technology that could support a "metabonomics" component in toxicological studies of drug candidates is presented. The hypothesis tested in this study was that FT-IR had sufficient resolving power to discriminate between urine collected from control rat populations and rats subjected to treatment with a potent inflammatory agent, bacterial lipopolysaccharide (LPS). It was also hypothesized that co-administration of LPS with ranitidine, a drug associated with reports of idiosyncratic susceptibility, would induce hepatotoxicity in rats and that this could be detected non-invasively by an FT-IR-based metabonomics approach. The co-administration of LPS with "idiosyncratic" drugs represents an attempt to develop a predictive model of idiosyncratic toxicity and FT-IR is used herein to support characterization of this model. FT-IR spectra are high dimensional and the use of genetic programming to identify spectral sub-regions that most contribute to discrimination is demonstrated. FT-IR is rapid, reagentless, highly reproducible and inexpensive. Results from this pilot study indicate it could be extended to routine applications in toxicology and to supporting characterization of a new animal model for idiosyncratic susceptibility.


Subject(s)
Spectroscopy, Fourier Transform Infrared/methods , Toxicity Tests/methods , Animals , Chemical and Drug Induced Liver Injury , Discriminant Analysis , Disease Susceptibility , Histamine H2 Antagonists/metabolism , Histamine H2 Antagonists/toxicity , Lipopolysaccharides/toxicity , Liver Diseases/urine , Male , Models, Animal , Pilot Projects , Ranitidine/toxicity , Rats , Rats, Sprague-Dawley , Spectroscopy, Fourier Transform Infrared/instrumentation , Spectroscopy, Fourier Transform Infrared/standards
6.
Mol Cell Biochem ; 247(1-2): 205-10, 2003 May.
Article in English | MEDLINE | ID: mdl-12841649

ABSTRACT

Chlorogenic acid (CGA) is considered to act as an antioxidant. However, the inhibitory effects of CGA on specific radical species are not well understood. Electron spin resonance (ESR) in combination with spin trapping techniques was utilized to detect free radicals. 5,5-Dimethyl-1-pyrroline-N-oxide (DMPO) was used as a spin trapping reagent while the Fenton reaction was used as a source of hydroxyl radical (*OH). We found that CGA scavenges *OH in a dose-dependent manner. The kinetic parameters, IC50 and Vmax, for CGA scavenging of *OH were 110 and 1.27 microM/sec, respectively. The rate constant for the scavenging of *OH by CGA was 7.73 x 10(9) M(-1) sec(-1). Our studies suggest that the antioxidant properties of CGA may involve a direct scavenging effect of CGA on *OH.


Subject(s)
Chlorogenic Acid/pharmacology , Hydroxyl Radical/chemistry , Chlorogenic Acid/chemistry , Cyclic N-Oxides/chemistry , Cyclic N-Oxides/pharmacology , Dose-Response Relationship, Drug , Electron Spin Resonance Spectroscopy , Free Radical Scavengers/chemistry , Free Radical Scavengers/pharmacology , Inhibitory Concentration 50 , Spin Trapping
SELECTION OF CITATIONS
SEARCH DETAIL
...